ArticleAnnals of neurology2020
Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy.
Article in Annals of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Retinal optical coherence tomography measures in multiple sclerosis: a systematic review and meta-analysis.Annals of clinical and translational neurology · 2024Pooled it
- Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease.Med (New York, N.Y.) · 2025Trial
- Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial.Neurology · 2023Trial
- Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Trial
- From Phenotypes to Spectrum: Rethinking RRMS, SPMS and PPMS in the Era of PIRA-A Framework Integrating PIRA, Smouldering-Associated Worsening, and Neurologic Reserve to Facilitate Earlier Recognition of Progression.Neurology international · 2026Review
- Optical Coherence Tomography Angiography Findings in Primary Progressive Multiple Sclerosis Patients Receiving Ocrelizumab Treatment.Diagnostics (Basel, Switzerland) · 2026Article
- The potential of optical coherence tomography angiography in progressive multiple sclerosis.Journal of neurology · 2026Article
- The impact of OSCAR-IB quality control and manual segmentation on retinal atrophy rates in multiple sclerosis.Frontiers in neurology · 2026Article
- Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort.European journal of neurology · 2025Article
- Fetal Growth Restriction Is Associated With Altered Optic Nerve Head Morphology in Term-Born Children and Adolescents.Investigative ophthalmology & visual science · 2025Article
- The Effects of Disease-Modifying Therapies on Optic Nerve Degeneration in Multiple Sclerosis.European journal of neurology · 2025Review
- Longitudinal analysis of retinal and choriocapillaris in patients with multiple sclerosis: a 3-year study.Journal of neurology · 2025Article
- 4D marmoset brain map reveals MRI and molecular signatures for onset of multiple sclerosis-like lesions.Science (New York, N.Y.) · 2025Article
- Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold.Annals of clinical and translational neurology · 2025Observational
- Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review.CNS neuroscience & therapeutics · 2025Review
- Assessment of the impact of reconstitution therapies-cladribine tablets and alemtuzumab-on the atrophy progression among patients with relapse-remitting multiple sclerosis.Frontiers in neuroscience · 2025Article
- Homonymous hemi-macular atrophy in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Assessing disease progression and treatment response in progressive multiple sclerosis.Nature reviews. Neurology · 2024Review
- Eye-brain connections revealed by multimodal retinal and brain imaging genetics.Nature communications · 2024Article
- Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis.Nature communications · 2024Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTherapeutic development in progressive multiple sclerosis (PMS) has been hampered by a lack of reliable biomarkers to monitor neurodegeneration. Optical coherence tomography (OCT)-derived retinal measures have been proposed as promising biomarkers to fulfill this role. However, it is unclear whether retinal atrophy persists in PMS, exceeds normal aging, or can be distinguished from relapsing-remitting multiple sclerosis (RRMS).
methods178 RRMS, 186 PMS, and 66 control participants were followed with serial OCT for a median follow-up of 3.7 years.
resultsThe estimated proportion of peripapillary retinal nerve fiber layer (pRNFL) and macular ganglion cell + inner plexiform layer (GCIPL) thinning in multiple sclerosis (MS) attributable to normal aging increased from 42.7% and 16.7% respectively at age 25 years, to 83.7% and 81.1% at age 65 years. However, independent of age, PMS was associated with faster pRNFL (-0.34 ± 0.09%/yr, p < 0.001) and GCIPL (-0.27 ± 0.07%/yr, p < 0.001) thinning, as compared to RRMS. In both MS and controls, higher baseline age was associated with faster inner nuclear layer (INL) and outer nuclear layer (ONL) thinning. INL and ONL thinning were independently faster in PMS, as compared to controls (INL:-0.09 ± 0.04%/yr, p = 0.03; ONL:-0.12 ± 0.06%/yr, p = 0.04), and RRMS (INL:-0.10 ± 0.04%/yr, p = 0.01; ONL:-0.13 ± 0.05%/yr, p = 0.01), whereas they were similar in RRMS and controls. Unlike RRMS, disease-modifying therapies (DMTs) did not impact rates of retinal layer atrophy in PMS.
interpretationPMS is associated with faster retinal atrophy independent of age. INL and ONL measures may be novel biomarkers of neurodegeneration in PMS that appear to be unaffected by conventional DMTs. The effects of aging on rates of retinal layer atrophy should be considered in clinical trials incorporating OCT outcomes. ANN NEUROL 2020;87:885-896.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.